Corporate Profile

HCW Biologics is a clinical-stage company advancing the development of transformative immunotherapies to lengthen healthspan by disrupting inflammaging.

HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.

 

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index

Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings
Filing date Description Form

ARS/A

ARS/A

Amendment to a previously filed 10-K

10-K/A

Report of unscheduled material events or corporate event

8-K

Quarterly report which provides a continuing view of a company's financial position

10-Q

Report of unscheduled material events or corporate event

8-K

Report of unscheduled material events or corporate event

8-K

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A